REPRO-MED Systems (KRMD) AI Stock Analysis

• Market Cap: $193.72M
• Dividend Yield: N/A
• Average Volume (3M): 90.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: 19.57%
• EPS Growth: 61.81%
• Country: US
• Employees: 80
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.01
• Shares Outstanding: 46,234,960
• 10 Day Avg. Volume: 84,054
• 30 Day Avg. Volume: 90,533
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.83
• Enterprise Value/Revenue: 4.36
• Enterprise Value/Gross Profit: 6.91
• Enterprise Value/Ebitda: -42.68
• 1Y Price Target: $5.00
• Price Target Upside: 20.77% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 55 Neutral
• Price Target: $4.00 ▼(-3.38% Downside)

The overall stock score of 55 reflects a company with strong revenue growth and promising international expansion, as highlighted in the earnings call. However, significant challenges in profitability, cash flow, and valuation metrics weigh heavily on the score. The technical analysis suggests moderate bullish momentum, but the negative P/E ratio and lack of dividends are concerning for investors.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and effective sales strategies, supporting long-term business sustainability and expansion.

International Expansion

The robust international expansion enhances market diversification and reduces dependency on domestic sales, strengthening global market presence.

Strategic Partnership

The partnership with ForCast Orthopedics expands product applications, potentially increasing market reach and driving future revenue growth.

Negative Factors

Profitability Challenges

Ongoing profitability challenges may hinder reinvestment in growth initiatives and affect long-term financial health and shareholder value.

Gross Margin Decline

Declining gross margins can pressure overall profitability, necessitating cost management improvements to sustain financial performance.

Cash Flow Concerns

Negative cash flows indicate potential liquidity issues, limiting the company's ability to fund operations and invest in growth opportunities.

REPRO-MED Systems Business Overview & Revenue Model

Company Description

REPRO-MED Systems, Inc. (KRMD) is a medical technology company specializing in the development and manufacturing of innovative medical devices and solutions for the healthcare sector. The company focuses primarily on the area of infusion therapy, providing products that improve the delivery of medications to patients with chronic conditions. Its core products include the proprietary infusion pump system, the FREEDOM60, designed for subcutaneous drug delivery, and other related accessories. REPRO-MED Systems operates in the medical device sector, targeting patients requiring home healthcare solutions, as well as healthcare providers and institutions.

How the Company Makes Money

REPRO-MED Systems generates revenue through the sale of its medical devices, primarily the FREEDOM60 infusion system and its associated accessories. The company's revenue model is based on direct sales to healthcare providers, distributors, and patients, as well as potential recurring revenue from consumable products related to its infusion systems. Key revenue streams include the initial sale of infusion pumps and ongoing sales of disposable components that require regular replacement. Additionally, partnerships with healthcare organizations and networks can enhance distribution capabilities and broaden market access, contributing to the company's overall earnings.

REPRO-MED Systems Financial Statement Overview

Summary

REPRO-MED Systems is experiencing revenue growth, but consistent losses and negative cash flows pose significant challenges. While the balance sheet shows a stable equity base and manageable debt levels, the company must address its operational inefficiencies to improve profitability and cash generation. Strategic cost management and revenue enhancement are crucial for future financial health.

Income Statement

The company shows a consistent growth trajectory in revenue with a 5% increase from the previous period to TTM. However, it struggles with profitability as evidenced by negative EBIT and net profit margins, indicating operational inefficiencies and high costs relative to revenue. The gross profit margin remains healthy, suggesting some control over direct costs.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.22, indicating prudent leverage. However, the return on equity is negative due to consistent net losses, which is a concern. The equity ratio of 60% indicates a solid capital structure with more equity financing, providing some financial stability.

Cash Flow

Cash flow analysis reveals challenges, as the company has negative operating cash flow and free cash flow, indicating potential liquidity issues. The free cash flow growth rate improved slightly, but remains negative, highlighting ongoing cash management challenges. The operating cash flow to net income ratio is unfavorable due to persistent losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	36.85M	33.65M	28.52M	27.90M	23.49M	24.18M
Gross Profit	23.27M	21.33M	16.71M	15.37M	13.77M	14.94M
EBITDA	-3.77M	-5.56M	-9.40M	-10.19M	-6.57M	1.61M
Net Income	-4.52M	-6.07M	-13.74M	-8.66M	-4.56M	-1.21M
Balance Sheet
Total Assets	25.52M	27.22M	28.46M	42.33M	41.29M	39.92M
Cash, Cash Equivalents and Short-Term Investments	8.05M	9.58M	11.48M	17.41M	25.33M	27.32M
Total Debt	3.47M	3.99M	4.45M	4.93M	604.14K	239.49K
Total Liabilities	8.99M	10.40M	8.11M	11.01M	4.79M	3.76M
Stockholders Equity	16.53M	16.81M	20.35M	31.33M	36.50M	36.16M
Cash Flow
Free Cash Flow	-2.17M	-1.62M	-5.71M	-8.21M	-4.69M	-1.80M
Operating Cash Flow	-682.14K	-319.72K	-4.89M	-5.40M	-4.32M	-743.32K
Investing Cash Flow	-1.53M	-1.33M	-814.60K	-2.80M	-366.17K	-1.04M
Financing Cash Flow	-194.03K	-248.53K	-218.87K	279.49K	2.71M	23.22M

REPRO-MED Systems Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.14
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRMD, the sentiment is Positive. The current price of 4.14 is above the 20-day moving average (MA) of 4.04, above the 50-day MA of 4.07, and above the 200-day MA of 3.51, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 59.89 is Neutral, neither overbought nor oversold. The STOCH value of 64.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KRMD.

REPRO-MED Systems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	71 Outperform	$195.61M	17.10	9.59%	2.00%	-16.64%	-13.64%
INFU	70 Outperform	$199.97M	42.41	9.39%	―	8.13%	1293.06%
KRMD	55 Neutral	$193.72M	―	-25.63%	―	19.57%	61.81%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OSUR	47 Neutral	$209.90M	-4.21	-12.65%	―	-49.35%	-285.61%

REPRO-MED Systems Corporate Events

KORU Medical Systems Reports Strong Q2 2025 Growth

KORU Medical Systems’ recent earnings call painted a picture of robust growth and strategic advancements, tempered by some operational challenges. The company reported significant revenue growth and international expansion, alongside advancements in product development and achieving positive cash flow. However, concerns were raised regarding a decline in gross margin and anticipated domestic inventory reductions.

KORU Medical Systems Reports Record Q2 2025 Results

KORU Medical Systems, Inc., a prominent player in the medical technology sector, specializes in developing, manufacturing, and commercializing large volume subcutaneous infusion solutions aimed at enhancing patient quality of life.